Hemostatic Matrix
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Blood Loss
Conditions
Blood Loss
Trial Timeline
Oct 1, 2007 → Aug 1, 2010
NCT ID
NCT00990288About Hemostatic Matrix
Hemostatic Matrix is a approved stage product being developed by Baxter for Blood Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00990288. Target conditions include Blood Loss.
What happened to similar drugs?
6 of 16 similar drugs in Blood Loss were approved
Approved (6) Terminated (6) Active (7)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00990288 | Approved | Completed |
Competing Products
20 competing products in Blood Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + voriconazole | Astellas Pharma | Approved | 35 |
| Cefiderocol | Shionogi | Phase 2 | 35 |
| Bunazosin + Doxazosin + Valsartin | Eisai | Approved | 43 |
| Pegfilgrastim | Kyowa Kirin | Phase 2 | 35 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 38 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 38 |
| epoetin alfa | Johnson & Johnson | Phase 2 | 35 |
| Metoprolol Succinate + Hydrochlorothiazide | AstraZeneca | Phase 3 | 40 |
| AZD6140 + Placebo | AstraZeneca | Phase 1 | 29 |
| NKTR-118 + moxifloxacin + Placebo | AstraZeneca | Phase 1 | 29 |
| MEDI-551 | AstraZeneca | Phase 1 | 29 |
| Ecallantide + Cyklokapron(R) | Merck | Phase 2 | 35 |
| Daptomycin | Merck | Phase 2 | 35 |
| ecallantide + placebo | Merck | Phase 2 | 35 |
| MK0859 | Merck | Phase 1 | 29 |
| Ecallantide + Placebo | Merck | Phase 2 | 27 |
| HSC835 | Novartis | Phase 2 | 35 |
| Aliskiren | Novartis | Approved | 35 |
| Aliskiren and HCTZ | Novartis | Approved | 43 |
| Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine | Novartis | Phase 2 | 35 |